sirukumab治疗类风湿关节炎的长期安全性与疗效:SIRROUND-LTE研究
SIRROUND-LTE是SIRROUND-D和SIRROUND-T的长期延伸研究,评估sirukumab在传统DMARD或抗TNF药物难治的中重度类风湿关节炎成人患者中的长期安全性和疗效。1820例患者入组,中位暴露时间在50mg每4周组为2.34年、100mg每2周组为2.07年。安全性与既往试验一致,疗效维持。
要点
- MACE在50mg每4周组更常见(2.2% vs 1.0%),注射部位反应在100mg每2周组更常见(7.5% vs 3.7%)。
- 最常见严重不良事件为感染(10%患者),32例(1.8%)死亡,主要死于严重感染和MACE。
- RA症状体征减少和身体功能改善在整个LTE期间维持。
核心结论
- sirukumab在长期延伸研究中的安全性特征与SIRROUND-D和SIRROUND-T报道的一致,且疗效维持。
研究设计与样本
- SIRROUND-D和SIRROUND-T研究的长期延伸(LTE)研究,纳入对传统DMARD或抗TNF药物难治的中重度RA成人患者。
- 患者接受sirukumab 100mg皮下每2周或50mg皮下每4周,共1820例入组。
主要发现
- 中位暴露时间在sirukumab 50mg每4周组为2.34年,100mg每2周组为2.07年。
- 不良事件发生率两组相似,但MACE在50mg每4周组更常见(2.2% vs 1.0%),注射部位反应在100mg每2周组更常见(7.5% vs 3.7%)。
- 最常见严重不良事件为感染(10%患者),32例(1.8%)死亡,主要死于严重感染和MACE,恶性肿瘤报告24例(1.3%)。
- 胃肠道穿孔、肝胆异常和实验室参数变化罕见。
- RA症状体征减少和身体功能改善在整个LTE期间维持。
关键数值与推荐
- MACE发生率:50mg每4周组2.2%,100mg每2周组1.0%。
- 注射部位反应发生率:100mg每2周组7.5%,50mg每4周组3.7%。
- 严重感染发生率:10%患者;死亡32例(1.8%);恶性肿瘤24例(1.3%)。
临床怎么用
- sirukumab长期治疗中需关注MACE和感染风险,尤其50mg每4周组MACE发生率较高。
- 100mg每2周组注射部位反应更常见,需做好患者教育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interleukin (IL)-6 is a pleiotropic cytokine involved in the pathophysiology of rheumatoid arthritis (RA). Sirukumab is a human monoclonal antibody that binds to IL-6 with high affinity and specificity. METHODS: This long-term extension (LTE) study of the SIRROUND-D and SIRROUND-T studies assessed long-term safety and efficacy of sirukumab in adults with moderate-to-severe RA refractory to conventional disease-modifying antirheumatic drug therapy or antitumor necrosis factor agents. Patients received sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) or sirukumab 50 mg SC every 4 weeks (q4w). RESULTS: 1820 patients enrolled in the LTE; median exposure was 2.34 and 2.07 years in sirukumab 50 mg q4w and 100 mg q2w groups, respectively. Adverse events (AEs) occurred in similar proportions between groups, with the exception of major adverse cardiovascular events (MACE), which were more common in the 50 mg q4w versus 100 mg q2w group (2.2% vs 1.0%), and injection-site reactions, more common in the 100 mg q2w group versus 50 mg q4w group (7.5% vs 3.7%). The most common serious AEs were infections (10% of the patients); 32 (1.8%) patients died during the study (primarily from serious infection and MACE). Malignancies were reported in 24 (1.3%) patients. Gastrointestinal perforations, hepatobiliary abnormalities and changes in laboratory parameters were rare. Reductions in RA signs and symptoms and improvements in physical function were maintained throughout the LTE. CONCLUSIONS: The safety profile of sirukumab in the LTE remained consistent with that reported in SIRROUND-D and SIRROUND-T and efficacy was maintained. TRIAL REGISTRATION NUMBER: NCT01856309.
引用
- Aletaha D, Bingham CO, Karpouzas GA, et al. Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). RMD Open. 2021. PMID: 33526709. doi:10.1136/rmdopen-2020-001465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。